The anti-cancer properties of heparin and its derivatives: a review and prospect

Heparin, including unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and heparin derivatives, are commonly used in venous thromboembolism treatment and reportedly have beneficial effects on cancer survival. Heparin can affect the proliferation, adhesion, angiogenesis, migration and i...

Full description

Saved in:
Bibliographic Details
Published inCell adhesion & migration Vol. 14; no. 1; pp. 118 - 128
Main Authors Ma, Sai-Nan, Mao, Zhi-Xiang, Wu, Yang, Liang, Ming-Xing, Wang, Dan-Dan, Chen, Xiu, Chang, Ping-an, Zhang, Wei, Tang, Jin-Hai
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.01.2020
Taylor & Francis Group
Subjects
cancer
Heparin
heparin derivatives
low-molecular-weight heparin
metastasis
Review
cancer
low-molecular-weight heparin
Heparin
metastasis
heparin derivatives
Online AccessGet full text

Cover

More Information
Summary:Heparin, including unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and heparin derivatives, are commonly used in venous thromboembolism treatment and reportedly have beneficial effects on cancer survival. Heparin can affect the proliferation, adhesion, angiogenesis, migration and invasion of cancer cells via multiple mechanisms. The main mechanisms involve inhibition of heparanase, P-/L-selectin, angiogenesis, and interference with the CXCL12-CXCR4 axis. Here we summarize the current experimental evidence regarding the anti-cancer role of heparin and its derivatives, and conclude that there is evidence to support heparin's role in inhibiting cancer progression, making it a promising anti-cancer agent.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors are contributed equally to this work.
Statement: All figures involved in this article are original,and there is no possibility that they were been reproduced from previously published sources.
ISSN:1933-6918
1933-6926
DOI:10.1080/19336918.2020.1767489